TRPV1 antagonistic analgesic effect: A randomized study of AZD1386 in pain after third molar extraction
H. Quiding(AstraZeneca (Sweden)), Märta Segerdahl, Ola Svensson(University of Borås), Lynn R. Webster(Adherent Technologies (United States)), Rolf Karlsten(Uppsala University), Annika Reimfelt(AstraZeneca (Sweden)), Bror Jonzon(AstraZeneca (Sweden)), Aleksandra Karin(AstraZeneca (Sweden))
Cited by 88
Related Papers
Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of the Opioid Risk Tool
|Pain Medicine|2005|1.1k
Risk Factors for Opioid-Use Disorder and Overdose
|Anesthesia & Analgesia|2017|504
Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities
|Nature Reviews Neurology|2020|504
Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain
|New England Journal of Medicine|2014|331
Sleep-Disordered Breathing and Chronic Opioid Therapy
|Pain Medicine|2007|309